| Literature DB >> 34948252 |
Bożena Bukowska1, Paulina Sicińska1.
Abstract
Epigenetic changes constitute one of the processes that is involved in the mechanisms of carcinogenicity. They include dysregulation of DNA methylation processes, disruption of post-translational patterns of histone modifications, and changes in the composition and/or organization of chromatin. Benzo(a)pyrene (BaP) influences DNA methylation and, depending on its concentrations, as well as the type of cell, tissue and organism it causes hypomethylation or hypermethylation. Moreover, the exposure to polyaromatic hydrocarbons (PAHs), including BaP in tobacco smoke results in an altered methylation status of the offsprings. Researches have indicated a potential relationship between toxicity of BaP and deregulation of the biotin homeostasis pathway that plays an important role in the process of carcinogenesis. Animal studies have shown that parental-induced BaP toxicity can be passed on to the F1 generation as studied on marine medaka (Oryzias melastigma), and the underlying mechanism is likely related to a disturbance in the circadian rhythm. In addition, ancestral exposure of fish to BaP may cause intergenerational osteotoxicity in non-exposed F3 offsprings. Epidemiological studies of lung cancer have indicated that exposure to BaP is associated with changes in methylation levels at 15 CpG; therefore, changes in DNA methylation may be considered as potential mediators of BaP-induced lung cancer. The mechanism of epigenetic changes induced by BaP are mainly due to the formation of CpG-BPDE adducts, between metabolite of BaP-BPDE and CpG, which leads to changes in the level of 5-methylcytosine. BaP also acts through inhibition of DNA methyltransferases activity, as well as by increasing histone deacetylases HDACs, i.e., HDAC2 and HDAC3 activity. The aim of this review is to discuss the mechanism of the epigenetic action of BaP on the basis of the latest publications.Entities:
Keywords: benzo(a)pyrene; carcinogenicity; histone modifications; lung cancer; methylation level; smoke
Mesh:
Substances:
Year: 2021 PMID: 34948252 PMCID: PMC8707600 DOI: 10.3390/ijms222413453
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Sources of BaP and its movement in the environment as well as ways of entering the human body.
Figure 2Epigenetic mechanisms contributing to gene regulation, DNA methylation, histone modifications, and noncoding RNAs (ncRNAs).
Figure 3TP53 gene and its role in the exposure to BaP [44,45,46].
Figure 4Prenatal exposure to PAHs and BaP and changes in methylation levels [50,51,52,58].
Figure 5The effect of BaP on various microRNAs levels in different cell types [53,62,63].
Potential epigenetic effects induced by BaP and its metabolite BPDE.
| Type of Epigenetic Change | Observed Effects | References | |
|---|---|---|---|
| Global methylation | Increased global metylation: | Mouse embryonic fibroblast cells | [ |
| Human bronchial epithelial cells (16HBE cells) | [ | ||
| Mouse embryonic fibroblast cells | [ | ||
| Normal human bronchial epithelial cells (NHBE) | [ | ||
| Decreased global methylation: | Human bronchial epithelial cell line (16HBE) | [ | |
| Zebrafish embryos | [ | ||
| Zebrafish embryos | [ | ||
| IRC mice | [ | ||
| Children, whose mothers smoked during pregnancy | [ | ||
| No changes in global methylation: | Human cells | [ | |
| TK6 cells | [ | ||
| Single gene promoters methylation | Increased methylation | [ | |
| [ | |||
| [ | |||
| [ | |||
| Biotinidase and holocarboxylase synthetaseHuman Bronchial Epithelial Cells (16HBE) | [ | ||
| 828 hypermethylated genes in rats | [ | ||
| Decreased methylation | 3 227 hypomethylated genes in rats | [ | |
| Decreased gene expression | [ | ||
| Histone modifications | Reduction in acetylation levels | Human bronchial epithelial cells (16HBE) | [ |
| Increase in histone deacetylases HDAC2 and HDAC3 | Human bronchial epithelial cells (16HBE) | [ | |
| Changes in H3K9 | Breast cancer cells (MCF7) | [ | |
| Changes | Decreased expression | miR-506 in cancer cells (16HBE-T) | [ |
| Increased expression | miR-638 in breast cancer (BRCA1) | [ | |
| mikroRNA-29b, mikroRNA-26a-1* i mikroRNA-122* (HepG2 cells) | [ | ||